This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving I-Mab Biopharma and Taysha Gene Therapies, as well as updates from Sanofi, Adcytherix and Boehringer Ingelheim that you may have missed. I-Mab Biopharma will change its name and pursue an initial public offering in Hong Kong as part of a transformation into a “hub-and-spoke” company with drugmaking subsidiaries. Following ...